Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenström macroglobulinaemia

Journal of Clinical Pathology

Volumn 64, Issue 6, 2011, Pages 520-523

  Pasricha, Sant Rayn ^a,b   Juneja, Surender K ^a,b,c   Westerman, David A ^b,c   Came, Neil A ^a,b,c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD20 ANTIGEN; HEMOGLOBIN; IMMUNOGLOBULIN M; SYNDECAN 1;

ADULT; AGED; ANEMIA; ARTICLE; B LYMPHOCYTE; BONE MARROW; BONE MARROW BIOPSY; CELL COMPARTMENTALIZATION; CLONAL VARIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LABORATORY TEST; LIGHT CHAIN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; THROMBOCYTE COUNT; WALDENSTROEM MACROGLOBULINEMIA;

BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN M; IMMUNOHISTOCHEMISTRY; MALE; PARAPROTEINS; PLASMA CELLS; WALDENSTROM MACROGLOBULINEMIA;

EID: 79956303454     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.088591     Document Type: Article

References (15)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinaemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:110-15. (Pubitemid 36506291)
2. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood 2009;113:4163-70.
3. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenström's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380-3.
4. Morice WG, Chen D, Kurtin PJ, et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Mod Pathol 2009;22:807-16.
5. Varghese AM, Rawstron AC, Ashcroft J, et al. Assessment of bone marrow response in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:53-5.
6. Swerdlow S, Berger F, Pileri S, et al. Lymphoplasmacytic lymphoma. In: Swerdlow S, Campo E, Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. Lyon: International Agency for Research on Cancer, 2008:194.
7. Ng AP, Wei A, Bhurani D, et al. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 2006;91:972-5. (Pubitemid 44023155)
8. Tuzuner N, Bennett JM. Reference standards for bone marrow cellularity. Leuk Res 1994;18:645-7. (Pubitemid 24249388)
9. Zhang QY, Foucar K. Bone marrow involvement by Hodkgin and non-Hodgkin lymphomas. Hematol Oncol Clin N Am 2009;23:873-902.
10. Wei A, Juneja S. Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol 2003;56:406-11. (Pubitemid 36724205)
11. Bartl R, Frisch B, Mahl G, et al. Bone marrow histology in Waldenström's macroglobulinaemia. Clinical relevance of subtype recognition. Scand J Haematol 1983;31:359-75. (Pubitemid 13005174)
12. Andriko JA, Aguilera NS, Chu WS, et al. Waldenström's macroglobulinemia: a clinicopathological study of 22 cases. Cancer 1997;80:1926-35. (Pubitemid 27479787)
13. Grogan TM. Plasma cell myeloma marrow diagnosis including morphologic and phenotypic features. Semin Diagn Pathol 2003;20:211-25. (Pubitemid 37169765)
14. Wei A, Westerman D, Feleppa F, et al. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica 2005;90:1147-9. (Pubitemid 41323522)
15. Gutierrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007;21:541-9.